Results 21 to 30 of about 39,896 (258)

All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population

Annals of General Psychiatry, 2019
Background Treatment-resistant depression (TRD) may represent a substantial proportion of major depressive disorder (MDD); however, the risk of mortality in TRD is still incompletely assessed. Methods Data were obtained from Optum Clinformatics™ Extended,
Gang Li, Daniel Fife, Grace Wang, John J. Sheehan, Robert Bodén, Lena Brandt, Philip Brenner, Johan Reutfors, Allitia DiBernardo   +8 more
doaj   +1 more source

Overcoming the myths of esketamine administration: different and not difficult

Frontiers in Psychiatry, 2023
Intranasal esketamine for treatment-resistant depression has been introduced and approved by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration practices were found different among countries. Major depression has a high impact
Florian Buchmayer, Siegfried Kasper
doaj   +1 more source

Bipolar mood disorder and treatment-resistant depression [PDF]

Annals of General Psychiatry, 2010
Two lines of evidence point to the relationship between bipolar mood disorder and treatment-resistant depression. First, the frequency of suboptimal response to antidepressant drugs is significantly higher in bipolar than in unipolar mood disorder. Secondly, the first and the second generation mood stabilizing drugs are efficacious for augmentation of ...
openaire   +2 more sources

Characterizing Treatment-Resistant Anorexia Nervosa

Frontiers in Psychiatry, 2021
Background: The issue of treatment resistance in eating disorder care is controversial. Prior research has identified multiple failed treatment attempts as a common criterion for severe and enduring anorexia nervosa, but little is known about patients ...
Sarah Smith, D. Blake Woodside, D. Blake Woodside   +2 more
doaj   +1 more source

Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder [PDF]

International Journal of Environmental Research and Public Health, 2018
Objectives: Extant evidence indicates that ketamine exerts rapid antidepressant effects in treatment-resistant depressive (TRD) symptoms as a part of major depressive disorder (MDD) and bipolar disorder (BD). The identification of depressed sub-populations that are more likely to benefit from ketamine treatment remains a priority.
Carola Rong, Caroline Park, Joshua D. Rosenblat, Mehala Subramaniapillai, Hannah Zuckerman, Dominika Fus, Yena L. Lee, Zihang Pan, Elisa Brietzke, Rodrigo B. Mansur, Danielle S. Cha, Leanna M. W. Lui, Roger S. McIntyre   +12 more
openaire   +3 more sources

Treatment Resistant Bipolar Disorder [PDF]

Psikiyatride Güncel Yaklaşımlar, 2015
Many patients diagnosed with bipolar disorder respond incompletely or unsatisfactorily to available treatments. Defining refractoriness in bipolar disorder is a complex issue and should concern and include either every phase and pole or the disorder as a
Elvan Ozalp, Ersin Hatice Karslioglu
doaj   +1 more source

Multidimensional Profiling of MRI‐Negative Temporal Lobe Epilepsy Uncovers Distinct Phenotypes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Although hippocampal sclerosis (TLE‐HS) represents the most frequent cause of temporal lobe epilepsy (TLE), up to 30% of patients show no lesion on visual MRI inspection (TLE‐MRIneg). These cases pose diagnostic and therapeutic challenges and are underrepresented in surgical series.
Alice Ballerini, Alessia Casarini, Niccolò Biagioli, Laura Mirandola, Daniela Ballotta, Paul Summers, Simona Scolastico, Laura Madrassi, Maurilio Genovese, Marcella Malagoli, Gaetano Cantalupo, Giada Giovannini, Matteo Pugnaghi, Niccolò Orlandi, Laura Tassi, Valeria Cuccarini, Domenico Aquino, Elena Tartara, Fulvia Palesi, Giuseppe Didato, Paolo Vitali, the 3TLE Study Group, Roberta Di Giacomo, Fabio Doniselli, Federica Mazzi, Carlo Andrea Galimberti, Claudia A. M. Gandini Wheeler‐Kingshott, Stefano Meletti, Anna Elisabetta Vaudano   +28 more
wiley   +1 more source

Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review

Frontiers in Psychiatry, 2020
There is a growing evidence for the rapid and robust antidepressive effect of ketamine in unipolar and bipolar treatment resistant depression although evidence for the risk of affective switch is still limited.
Alina Wilkowska, Łukasz Szałach, Jakub Słupski, Aleksandra Wielewicka, Małgorzata Czarnota, Maria Gałuszko-Węgielnik, Mariusz S. Wiglusz, Wiesław J. Cubała   +7 more
doaj   +1 more source

The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States

The Journal of Clinical Psychiatry, 2021
Estimates of prevalence and burden of treatment-resistant depression (TRD) vary widely in the literature. This study evaluated the prevalence and burden of TRD and the share of TRD in the burden of medication-treated major depressive disorder (MDD) using the most commonly accepted definition of TRD and a novel bottom-up approach.Prevalence and health ...
Maryia, Zhdanava, Dominic, Pilon, Isabelle, Ghelerter, Wing, Chow, Kruti, Joshi, Patrick, Lefebvre, John J, Sheehan   +6 more
openaire   +3 more sources

Could ketamine be the answer to treating treatment‐resistant major depressive disorder? [PDF]

General Psychiatry, 2020
Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350 million people worldwide, which remains to be unsatisfactorily treated with 53% of patients still complaining of symptoms after completing their courses with the correct dosage. Ketamine, which was approved by the Food and Drug Administration
Ramadan, Abdullah Mohammed, Mansour, Islam Ahmed   +1 more
openaire   +2 more sources